Screener
Kura Oncology KURA Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The source filing: Kura Oncology’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219481
| Line item | March 31, 2026 | December 31,2025 |
|---|---|---|
| Current operating lease liabilities | 1,283 | 1,277 |
| Current portion of contract liabilities | 47,704 | 48,983 |
| Total current liabilities | 101,496 | 116,974 |
| Long-term debt, net | 9,749 | 9,711 |
| Long-term operating lease liabilities | 13,241 | 9,469 |
| Other long-term liabilities | 3,437 | 3,165 |
| Long-term contract liabilities | 416,745 | 424,909 |
| Total liabilities | 544,668 | 564,228 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Kura Oncology's long-term debt?
- Kura Oncology (KURA) reported long-term debt of $9.75M in Q1 2026.
- How has Kura Oncology's long-term debt changed year-over-year?
- Kura Oncology's long-term debt increased by 27.4% year-over-year, from $7.65M to $9.75M.
- What is the long-term trend for Kura Oncology's long-term debt?
- Over 4 years (2020 to 2025), Kura Oncology's long-term debt has grown at a 22.9% compound annual growth rate (CAGR), from $4.25M to $9.71M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Kura Oncology's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude